You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥(6996.HK)12月10日召開產品獲批發佈會
格隆匯 12-17 17:47
格隆匯12月17日丨致力於研發和商業化同類首款及/或同類最優血液及實體腫瘤療法的領先創新生物製藥公司——德琪醫藥(6996.HK)將於12月20日(週一)10:00-11:00召開電話會議旨在溝通塞利尼索國內獲批情況,該產品是公司首個進入商業化階段的創新藥。創始人、董事長兼首席執行官梅建明博士,首席科學官單波博士,首席財務官龍振國先生,中國血液腫瘤事業部負責人於立新先生,臨牀研究執行總監王愛華博士,董事會祕書、投資者關係兼財務總監曹洋先生將出席本次電話會議,具體撥入方式見下圖:

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account